Magnevist (gadopentetate dimeglumine) is a gadolinium based MRI contrast dye manufactured by Bayer-Schering and its subsidiary Berlex Laboratories. Like other gadolinium contast dyes, Magnevist is used by medical professionals to improve the visibility of organs during MRIs. In most patients, gadolinium is rapidly cleared from the body by the kidneys following the procedure. However, patients with kidney problems may be unable to eliminate gadolinium from their bodies, leaving them at risk for developing serious complications.

On May 23, 2007, the Food and Drug Administration (FDA) requested that Bayer-Schering add a new boxed warning on Magnevist because it had been linked to Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy in MRI patients with renal problems. NSF / NFD is a disease that causes fibrosis of body organs, resulting in the inability of the organs to work properly. NSF can be fatal and there is no known cure.

Magnevist has also been the subject of legal action. In June 2008, a gadolinium lawsuit was filed against Bayer-Schering and Berlex Laboratories by a Minnesota woman who claims that she developed NSF after an imaging scan using Magnevist gadolinium contrast dye. She has suffered from permanent disability and severe disfigurement caused by NSF. The lawsuit alleges that Magnevist is defective, that the defendants failed to adequately test it, and that the defendants failed to warn patients about its potential to cause NSF.

If you or a loved one has been diagnosed with Nephrogenic Systemic Fibrosis following an MRI or MRA in which Magnevist was used as a contrast agent, you may be eligible to participate in a gadolinium lawsuit. In order to ensure that your legal rights are protected, fill out the form on this page for a free case evaluation.